Covid-19 roundup: AstraZeneca, Pfizer come under fire for production delays; Moderna considers third booster dose to squash new variants
The vaccine race is shaping up to be much more than just a sprint toward authorization.
A day after Merck dropped out entirely, controversies …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
